Phase 2 N=7 Lucentis for Inflammatory Macular Edema Trial
Uveitis · Cytoid Macular Edema
Primary: The Mean Change at 3 Months in BSCVA From Baseline — 13 letters
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=8 Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)
Uveitis
Primary: Number of Participants Experiencing a Treatment Response by Week 16 — 4; 2 Participants
Phase 2 N=43 Proof of Concept Study to Evaluate Safety and Efficacy of LME636 in the Treatment of Acute Anterior Uveitis
Acute Anterior Uveitis
Primary: Number of Responders at Day 15 — 14; 9 Participants
Phase 4 N=5 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients
Uveitis · Anterior Uveitis · Intermediate Uveitis
Primary: Number of Participants With Photographic Haze Reduced to Grade 0 or Down 2 Steps Documented With Fundus Photography — 3; 1; 1 Participants
Phase 2 N=10 Abatacept in the Treatment of Uveitis
Uveitis
Primary: Adverse Events — 0; 0; 0 Participants
Phase 3 N=38 Suprachoroidal Injection of CLS-TA in Patients With Non-infectious Uveitis
Uveitis · Uveitis, Posterior · Uveitis, Anterior
Primary: Adverse Events — 27; 1 Participants
N/A N=18 PEMF: an Adjunct Therapy for Anterior Uveitis
Anterior Uveitis · Iritis
Primary: Inflammation Grade at Day 7 — 0.625; 1.444 units on a scale
Phase 4 N=255 Multicenter Uveitis Steroid Treatment (MUST) Trial
Uveitis
Primary: Change in Best-corrected Visual Acuity (Change in the Numbers of Letters Read From a Standard ETDRS Eye Chart) From Baseline to 24 Months in Eyes With Uveitis — 6.0; 3.2…
Phase 2 N=45 A Safety and Efficacy Study of NS2 in Patients With Anterior Uveitis
Non-infectious Anterior Uveitis
Primary: Anterior Chamber Cell Grade at Week 8 — -0.7; -0.9; -0.5 units on a scale
Phase 2 N=16 Safety and Efficacy of AIN457 in Noninfectious Uveitis
Non-infectious Uveitis
Primary: Number of Participants With Adverse Events (AEs), Serious Adverse Events (SAEs) and Who Died — 0; 0; 1; 1 participants
Phase 3 N=153 Safety and Efficacy Study of a FAI Insert in Subjects With Chronic Non-infectious Posterior Uveitis
Posterior Uveitis · Intermediate Uveitis · Panuveitis
Primary: Number of Participants With Recurrence of Uveitis in Study Eye Within 6 Months — 28; 22 Participants
Phase 2 N=31 Optiquel® as Corticosteroid-sparing Therapy for Chronic Noninfectious Uveitis
Uveitis
Primary: The Primary Outcome is the Time to Recurrence of Uveitis in Participants of Each Treatment Group, During or After Tapering of Oral Prednisone to a Dose of 7.5 mg/Day, or…
Early Phase 1 N=49 Assessment of the Anti-inflammatory Effects of Norflo Oro in Acute Relapses of HLA-B27 Associated Autoimmune Uveitis
Uveitis
Primary: Change in Mean Number of Uveitis Relapses Per Patient Between the 12 Month Study Period Compared to Baseline — 0.35; 0.58 Relapses Per Patient
Phase 3 N=123 SOLACE Trial - A Phase 3 Trial in Subjects With Non-infectious Anterior-uveitis.
Non-infectious Anterior Uveitis
Primary: Number of Subjects Who Meet Time to Clearance of Anterior Chamber Cells — 25; 24 Subjects
Phase 3 N=261 Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis
Uveitis
Primary: Time to Treatment Failure on or After Week 2 — 8.3; NA; 5.6; NA months — p=0.004
Phase 3 N=239 Efficacy and Safety of Adalimumab in Patients With Active Uveitis
Uveitis
Primary: Time to Treatment Failure on or After Week 6 — 3.0; 5.6; 3.0; 4.8 months — p=<0.001
Phase 3 N=139 A Study of TRS01 in Subjects With Active Non-infectious Anterior Uveitis Including Subjects With Uveitic Glaucoma
Non-infectious Anterior Uveitis · Uveitic Glaucoma
Primary: Anterior Chamber Cell (ACC) Grade = 0 on Day 28 — 38; 32; 44; 15 Participants
Phase 3 N=227 Adalimumab vs. Conventional Immunosuppression for Uveitis Trial
Uveitis
Primary: Corticosteroid-sparing Treatment Success Within the First 6 Months After Randomization — 0.69; 0.54 Cumulative proportion of participants — p=0.029
Phase 2 N=16 A Study to Evaluate TRS01 Eye Drops in Participants With Active Non-infectious Anterior Uveitis
Non-infectious Anterior Uveitis
Primary: Assessment of Both Systemic and Ocular Adverse Events — 2; 5 Participants
Phase 1 N=6 Efalizumab to Treat Uveitis
Uveitis · Macular Edema
Primary: Number of Participants With Systemic Toxicities, Adverse Events, or Infections — 6 Participants
Phase 2 N=22 Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis
Uveitis · Macular Edema · Uveitis, Posterior
Primary: Change From Baseline in Central Subfield Thickness, Measured Using Optical Coherence Tomography, After Treatment With CLS-TA in Subjects With Macular Edema Following…
Phase 4 N=21 Re-implantation of a Fluocinolone Acetonide Implant for Non-infectious Uveitis Affecting the Posterior Segment
Uveitis
Primary: Number of Eyes With Inflammation Recurrence — 1 eye with inflammation
Phase 3 N=160 Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis
Uveitis · Uveitis, Posterior · Uveitis, Anterior
Primary: Number of Subjects Demonstrating ≥ 15 Letter Improvement From Baseline in Best Corrected Visual Acuity at 24 Weeks — 45; 10 Participants — p=<0.001
Phase 3 N=110 Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis
Endogenous Anterior Uveitis
Primary: Change From Baseline (Day 0) in Anterior Chamber Cell Grade at Day 14 — 2.6; 2.6; -2.2; -2.0 Units on a scale
Phase 4 N=89 A Study to Assess the Effects of Certolizumab Pegol on the Reduction of Anterior Uveitis (AU) Flares in Axial Spondyloarthritis Subjects With a Documented History of AU
Axial Spondyloarthritis (axSpA) · Anterior Uveitis (AU)
Primary: Number of Distinct Episodes of Anterior Uveitis (AU) Flares During the Treatment Period — 1.9; 0.3 flares — p=<0.001
Phase 2 N=31 Adalimumab (Humira) in the Treatment of Refractory Non-infectious Uveitis
Uveitis
Primary: Cumulative Endpoint — 21 participants
Phase 3 N=424 A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis
Uveitis
Primary: Number of Participants With Adverse Events — 398; 101 participants
Phase 3 N=118 Phase III Study in Refractory Behcet's Disease
Behcet Disease
Primary: Rate of Recurrent Ocular Exacerbations in the Study Eye During 24 Weeks by Treatment — 7.7; 11.5; 7.7 Ocular Exacerbations
N/A N=5 Pegaptanib Therapy in Non-Infectious Uveitic Cystoid Macular Edema
Uveitis · Cystoid Macular Edema
Primary: Improvement in VA ETDRS >/= 15 Letters — 1 participants
Phase 4 N=20 Study of the Effectiveness of Ozurdex for the Control of Uveitis
Uveitis, Intermediate · Uveitis, Posterior
Primary: Number of Participants With Absence of Intraocular Inflammation at 6 Months — 12 Participants